Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2010

View Archived Issues

MedImmune reports clinical data on asthma candidates MEDI-563 and MEDI-528

PH-797804 improves lung function in patients with COPD

Preclinical and clinical data reported on neoglycoside ACHN-490

Intranasal XF-73 well tolerated in phase I study

Phase I data support safety of TissueGene-C in osteoarthritis

Plexxikon discloses new inhibitors of protein kinases

Maximum tolerated dose of ARRY-380 established in patients with breast cancer

Achillion begins dosing in phase IIa trial of ACH-1625 in HCV infection

Global marketing rights to Caelyx to transition from Merck & Co. to Janssen

Eisai and Anaeropharma partner to discover Bifidobacterium-delivered anticancer agents

Barcelona researchers claim new apoptosis inducers

Trophos begins clinical development of TRO-40303

Embera NeuroTherapeutics obtains NIDA grant for EMB-001 development

Pierre Fabre Medicament discloses new 11-beta-HSD1 inhibitors

Argenta and Janssen enter into cancer drug discovery agreement

Cortex Pharma regains rights to Ampakine agents for depression and schizophrenia

Merck Serono discovers new lysophospholipid S1P1 receptor antagonists

Cellceutix completes toxicity studies of anticancer agent Kevetrin

SEPS Pharma presents new antifungal agents

CHMP recommends variation to terms of marketing authorization for Invega

AcelRx completes end-of-phase II meeting with FDA on ARX-02 Sufentanil NanoTab

GSK discontinues Simplirix development for genital herpes

Biomarker analysis demonstrates potential of MGN-1703 against cancer

PEGASUS-TIMI 54 trial to evaluate long-term post-ACS efficacy and safety of ticagrelor

GW Pharma begins phase IIa trial of cannabinoids in type 2 diabetes

FDA requests change in tapentadol ER formulation in complete response letter to J&JPRD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.